Caris Life Sciences price target raised to $35 from $25 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $25 and keeps an Overweight rating on the shares. The firm updated models…
Fiscal Year: January - December
Caris Life Sciences, Inc. (CAI), listed on the NASDAQ, has a market capitalization of $8.64B. As of Oct 19, 2026, the stock is trading at $30.56 per share@else an unavailable price , offering investors a clear view of its current market value. Caris Life Sciences, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 82.38, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Caris Life Sciences, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Caris Life Sciences, Inc. (CAI). A fair value is shown for companies with at least three years of reported free cash flow and a positive typical free cash flow margin. Banks, insurers and REITs need a different valuation model and are not covered yet.
The proprietary SS Score for Caris Life Sciences, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Caris Life Sciences, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Caris Life Sciences, Inc. is 69.67, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Caris Life Sciences, Inc. (CAI) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Caris Life Sciences, Inc. (CAI) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Caris Life Sciences, Inc. (CAI) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Caris Life Sciences, Inc.. To access the full SS Score, consider upgrading your subscription.
Caris Life Sciences, Inc. is a significant player in the industry sector, with a market capitalization of $8.64B and a competitive P/E ratio of 82.38. Investors should compare these metrics with industry peers to gauge whether Caris Life Sciences, Inc. is outperforming or underperforming within its sector.
JPMorgan analyst Casey Woodring raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $25 and keeps an Overweight rating on the shares. The firm updated models…
TD Cowen analyst Dan Brennan raised the firm’s price target on Caris Life Sciences (CAI) to $36 from $30 and keeps a Buy rating on the shares. The firm adjusted…
BofA raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $23 and keeps a Buy rating on the shares as part of a specialty diagnostics group…
UBS initiated coverage of Caris Life Sciences (CAI) with a Neutral rating and $28 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views…
Caris Life Sciences (CAI) announced that researchers from Caris and the Caris Precision Oncology Alliance will present seven studies at the International Association for the Study of Lung Cancer, IASL...
BTIG raised the firm’s price target on Caris Life Sciences (CAI) to $33 from $32 and keeps a Buy rating on the shares.
Evercore ISI raised the firm’s price target on Caris Life Sciences (CAI) to $26 from $25 and keeps an Outperform rating on the shares.
Reports Q2 revenue $263.7M, consensus $238.08M. “This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from inv...
16:28 EDT Caris Life Sciences (CAI) sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco
TD Cowen lowered the firm’s price target on Caris Life Sciences (CAI) to $30 from $31 and keeps a Buy rating on the shares. The firm adjusted targets in the…
Caris Life Sciences (CAI) will offer in-house PTEN immunohistochemistry, or IHC, testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is...
BofA lowered the firm’s price target on Caris Life Sciences (CAI) to $23 from $28 and keeps a Buy rating on the shares as part of the firm’s Q2 earnings…
Evercore ISI lowered the firm’s price target on Caris Life Sciences (CAI) to $25 from $30 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech,…
Caris Life Sciences (CAI) announced the commercial launch of Caris Detect, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages...
Caris Life Sciences (CAI) announced the dual listing of its common stock on NYSE Texas effective on June 17, further expanding its presence in the public markets. Caris’ shares will…
Caris Life Sciences (CAI) announced that its Board of Directors has authorized a share repurchase program for up to $100M of the company’s outstanding common stock.
Wolfe Research assumed coverage of Caris Life Sciences (CAI) with a Peer Perform rating and no price target The firm is positive on the company’s tissue therapy selection dominance but…
Wolfe Research analyst Mike Polark downgraded Caris Life Sciences (CAI) to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock. Published first on…
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.